Clinical Trial Update: Pembrolizumab as Neoadjuvant Treatment in HCC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pembrolizumab as neoadjuvant therapy for hepatocellular carcinoma. Sponsor: Kindai University; current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Kindai University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN